Effects of aminoguanidine on latent murine tuberculosis

Journal of Immunology

Volumn 160, Issue 4, 1998, Pages 1796-1803

  Flynn, Joanne L ^a   Scanga, Charles A ^a   Tanaka, Kathryn E ^b   Chan, John ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; ANTIMYCOBACTERIAL AGENT; CYTOKINE; GAMMA INTERFERON; ISONIAZID; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROGEN DERIVATIVE; PYRAZINAMIDE; REACTIVE NITROGEN INTERMEDIATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; FEMALE; GRANULOMATOSIS; HEPATOSPLENOMEGALY; LATENT PERIOD; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REINFECTION; TUBERCULOSIS;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME INDUCTION; FEMALE; GUANIDINES; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RECURRENCE; TIME FACTORS; TUBERCULOSIS;

EID: 0032519735     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Stead, W. W., G. R. Kerby, D. P. Schieuter, and C. W. Jordahl. 1968. The clinical spectrum of primary tuberculosis in adults: confusion with reinfection in the pathogenesis of chronic tuberculosis. Ann. Intern. Med. 68:731.
2. Stead, W. W. 1967. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? Am. Rev. Respir. Dis. 95:729.
3. Anonymous. 1990. The use of preventive therapy for tuberculous infection in the United States: recommendations of the Advisory Committee for Elimination of Tuberculosis. Morb. Mortal. Wkly. Rep. 39:9.
4. Stead, W. W. 1965. The pathogenesis of pulmonary tuberculosis among older persons. Am. Rev. Respir. Dis. 91:811.
5. Chan, J., and S. H. E. Kaufmann. 1994. Immune mechanisms of protection. In Tuberculosis: Pathogenesis, Protection and Control. B. R. Bloom, ed. American Society for Microbiology, Washington, DC, pp. 389-415.
6. Haas, D. W., and R. M. des Perez. 1995. Mycobacterium tuberculosis. In Principles and Practice of Infectious Diseases. G. L. Mandell, J. E. Bennett, and R. Dolin, eds. Churchill Livingstone, New York, pp. 2213-2243.
7. Snider, D. E. J., and W. L. Roper. 1992. The new tuberculosis. N. Engl. J. Med. 326:703.
8. Barnes, P. F., A. B. Bloch, P. T. Davidson, and D. E. Snider, Jr. 1991. Tuberculosis in patients with human immunodeficiency virus infection. N. Engl. J. Med. 234:1644.
9. Selwyn, P. A., D. Hartel, V. A. Lewis, E. E. Schoenbaum, S. H. Vermund, R. S. Klein, A. T. Walker, and G. H. Freidland. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N. Engl. J. Med. 320:545.
10. Chan, J., Y. Xing, R. Magliozzo, and B. R. Bloom. 1992. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175:1111.
11. Denis, M. 1991. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell. Immunol. 132:150.
12. Chan, J., K. Tanaka, D. Carroll, J. L. Flynn, and B. R. Bloom. 1995. Effect of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect. Immun. 63:736.
13. Flynn, J. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom. 1993. An essential role for Interferon-γ in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249.
14. Flynn, J. L., M. M. Goldstein, J. Chan, K. J. Triebold, K. Pfeffer, C. J. Lowenstein, R. Schreiber, T. W. Mak, and B. R. Bloom. 1995. Tumor necrosis factor-α is required in the protective immune response against M. tuberculosis in mice. Immunity 2:561.
15. Swanson, P. E. 1994. Microwave antigen retrieval in citrate buffer. Lab. Med. 25:520.
16. Cattoretti, G., M. H. G. Becker, and G. Key. 1992. Monoclonal antibodies against recombinant parts of the Ki-678 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed tissue sections. J. Pathol. 168:357.
17. Flynn, J. L., M. M. Goldstein, K. J. Triebold, J. Sypek, S. Wolf, and B. R. Bloom. 1995. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155:2515.
18. Reiner, S. L., S. Zheng, D. B. Corry, and R. M. Locksley. 1993. Constructing polycompetitor cDNAs for quantitative PCR. J. Immunol. Methods 165:37.
19. Orme, I. M. 1988. A mouse model of the recrudescence of latent tuberculosis in the elderly. Am. Rev. Respir. Dis. 137:716.
20. McCune, R. M., and R. Tompsett. 1957. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy. J. Exp. Med. 104:737.
21. McCune, R. M., R. Tompsett, and W. McDermott. 1957. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J. Exp. Med. 104:763.
22. McCune, R. M., F. M. Feldmann, H. P. Lambert, and W. McDermott. 1966. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123:445.
23. McCune, R. M., F. M. Feldmann, and W. McDermott. 1966. Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli. J. Exp. Med. 123: 469.
24. Grosset, J. 1978. The sterilizing value of rifampicin and pyrazinamide in experimental short course chemotherapy. Tubercle 59:287.
25. Orme, I. M., and F. M. Collins. 1994. Mouse model of tuberculosis. In Tuberculosis: Pathogenesis, Protection, and Control. B. R. Bloom, ed. American Society for Microbiology, Washington, DC, pp. 113-134.
26. Rees, R. J. W., and D.'A. Hart. 1961. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br. J. Exp. Pathol. 42:83.
27. Tilton, R. C., K. Chang, J. A. Corbett, T. P. Misko, M. G. Currie, N. S. Bora, H. J. Kaplan, and J. R. Williamson. 1994. Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest. Ophthal. Vis. Sci. 35:3278.
28. Beckerman, K. P., H. W. Rogers, J. A. Corbett, R. D. Schreiber, M. L. McDaniel, and E. R. Unanue. 1993. Release of nitric oxide during the T cell independent pathway of macrophage activation. J. Immunol. 150:888.
29. Nathan, C. 1992. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6:3051.
30. Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffen, D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in IFN-γ gene-disrupted mice. J. Exp. Med. 178:2243.
31. Adams, L. B., C. M. Mason, J. K. Kolls, D. Scollard, J. L. Krahenbuhl, and S. Nelson. 1995. Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovirus. J. Infect. Dis. 171:400.
32. O'Brien, L., J. Carmichael, D. B. Lowrie, and R. W. Andres. 1994. Strains of Mycobacterium tuberculosis differ in susceptibility to reactive nitrogen intermediates in vitro. Infect. Immun. 62:5187.
33. Rhoades, E. R., and I. M. Orme. 1997. Susceptibility of panel of virulent strains of Mycobacterium tuberculosis to reactive nitrogen intermediates. Infect. Immun. 65:1189.
34. Nicholson, S., M. Bonecini-Almeida, J. R. L. Silva, C. Nathan, Q.-w. Xie, R. Mumford, J. R. Weidner, J. Calaycay, J. Geng, N. Boechat, C. Linhares, W. Rom, and J. L. Ho. 1996. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J. Exp. Med. 184:2293.
35. MacMicking, J. D., R. J. North, R. LaCourse, J. S. Mudgett, S. K. Shah, and C. F. Nathan. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl. Acad. Sci. USA 94:5243.
36. Stenger, S., N. Donhaur, H. Thuring, M. Rollinghoff, and C. Bogdan. 1996. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 183:1501.
37. Seiler, N., B. Knodgen, and K. Haegele. 1882. N-(3-aminopropyl) pyrrolidin-2-one, a product of spermidine catabolism in vivo. Biochem. J. 208:189.
38. Kuzuya, M., S. Satake, H. Miura, T. Hayashi, and A. Iguchi. 1996. Inhibition of endothelial cell differentiation on a glycosylated reconstituted basement membrane complex. Exp. Cell Res. 226:336.
39. Seiler, N., F. N. Bolkenius, and B. Knodgen. 1985. The influence of catabolic reactions on polyamine excretion. Biochem. J. 225:219.
40. Bucala, R., K. J. Tracey, and A. Cerami. 1991. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest. 87:432.
41. Bloom, B. R., and C. Murray. 1992. Tuberculosis: commentary on a reemergent killer. Science 257:1055.
42. Dolin, P. J., M. C. Raviglione, and A. Kochi. 1994. Global tuberculosis incidence and mortality during 1990-2000. Bull. W. H. O. 72:213.